INT147636

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.60
First Reported 2007
Last Reported 2008
Negated 0
Speculated 0
Reported most in Body
Documents 3
Total Number 3
Disease Relevance 1.27
Pain Relevance 1.73

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (CD80) intracellular (CD80) cell-cell signaling (CD80)
Anatomy Link Frequency
T-cell 3
CD80 (Homo sapiens)
Pain Link Frequency Relevance Heat
abatacept 184 99.74 Very High Very High Very High
rheumatoid arthritis 33 99.64 Very High Very High Very High
Infliximab 93 95.32 Very High Very High Very High
methotrexate 23 93.64 High High
psoriasis 1 38.00 Quite Low
tolerance 1 12.32 Low Low
corticosteroid 4 5.00 Very Low Very Low Very Low
cINOD 4 5.00 Very Low Very Low Very Low
Pain 3 5.00 Very Low Very Low Very Low
Rheumatism 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Rheumatoid Arthritis 33 99.64 Very High Very High Very High
Disease 15 93.48 High High
Infection 16 92.24 High High
Cancer 3 68.32 Quite High
Necrosis 2 67.76 Quite High
Anaerobic Bacterial Infections 32 50.00 Quite Low
Psoriasis 1 38.00 Quite Low
Mycobacterial Infection 8 5.00 Very Low Very Low Very Low
Pneumonia 4 5.00 Very Low Very Low Very Low
Opportunistic Infections 4 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Abatacept selectively modulates the CD80/CD86:CD28 co-stimulatory signal required for full T-cell activation, and has been approved for the treatment of rheumatoid arthritis (RA) in combination with methotrexate in a number of countries, including the United States, Canada, and the European Union.
Regulation (modulates) of CD80 in T-cell associated with rheumatoid arthritis, abatacept and methotrexate
1) Confidence 0.60 Published 2007 Journal Clin. Exp. Rheumatol. Section Abstract Doc Link 17977488 Disease Relevance 0.37 Pain Relevance 0.52
Abatacept is a selective T-cell co-stimulation modulator, that modulates the CD80/CD86:CD28 co-stimulatory signal required for full T-cell activation.1 The mechanism of action of abatacept is fundamentally different to that of other biological disease-modifying antirheumatic drugs (DMARDs) for the treatment of rheumatoid arthritis (RA).
Regulation (modulates) of CD80 in T-cell associated with rheumatoid arthritis, abatacept and disease
2) Confidence 0.26 Published 2008 Journal Annals of the Rheumatic Diseases Section Body Doc Link PMC2564802 Disease Relevance 0.63 Pain Relevance 0.64
Abatacept is the first in a class of agents for the treatment of RA that selectively modulates the CD80/CD86:CD28 co-stimulatory signal required for full T-cell activation [4].
Regulation (modulates) of CD80 in T-cell associated with rheumatoid arthritis and abatacept
3) Confidence 0.23 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC1906816 Disease Relevance 0.26 Pain Relevance 0.57

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox